Wendy future of retail top

DIR fees

Rep. Tom Suozzi visits N.Y. specialty pharmacy

Rep. Tom Suozzi visits N.Y. specialty pharmacy

GREAT NECK, N.Y. — Rep. Tom Suozzi (D., N.Y.) gauged cost dynamics of the specialty pharmacy market in a tour of oncology pharmacy Onco360 here with members of the National Association of Specialty Pharmacy (NASP). Seeking insight on what’s driving skyrocketing drug costs and the impact on patients, Suozzi met with Sheila Arquette, executive director

Senate hearing scrutinizes prescription drug costs

Senate hearing scrutinizes prescription drug costs

WASHINGTON — Pharmacy benefit managers are a key focus of debate about elevated drug pricing that has come before a U.S. Senate committee. The National Community Pharmacists Association (NCPA) and the Senior Care Pharmacy Coalition (SCPC) called for PBM reform in written testimony submitted to a Senate Health, Education, Labor and Pensions (HELP) Committee hearing

Controversy over DIR under Medicare Part D heats up

Controversy over DIR under Medicare Part D heats up

Direct and indirect remuneration (DIR) is one component of the complex Medicare Part D payment system. In the past several months, the issue of DIR increasingly has become a source of contention between various players in the Part D program. Pharmacies, the Centers for Medicare and Medicaid Services (CMS), and members of Congress have expressed

Coalition trains fire on DIR fees under Medicare Part D

Coalition trains fire on DIR fees under Medicare Part D

ALEXANDRIA, Va. — A group 118 health care stakeholders, including chain drug retailers, have called on Congress to crack down on direct and indirect remuneration (DIR) fees in Medicare Part D. Mobilized by the National Community Pharmacists Association (NCPA), the broad coalition sent letters to the Senate and House of Representatives to voice their support

Congress urged to move on DIR fee legislation

Congress urged to move on DIR fee legislation

ALEXANDRIA, Va. — Chain drug retailers were among 118 health care stakeholders calling on Congress this week to crack down on direct and indirect remuneration fees in Medicare Part D. Marshaled by the National Community Pharmacists Association, the broad coalition — also including independent pharmacies, pharmacy trade groups, drug distributors, pharmacy buying groups, supermarket retailers,

NCPA nudges Congress to act on DIR fee bills

NCPA nudges Congress to act on DIR fee bills

ALEXANDRIA, Va. — The National Community Pharmacists Association has called on Congress to hold hearings on legislation that would crack down on direct and indirect remuneration (DIR) fees. NCPA said it has sent letters to the chair and ranking member of the Senate Finance Committee and to the chair and ranking members of the House

Congress reintroduces DIR fee legislation

Congress reintroduces DIR fee legislation

WASHINGTON — Reps. Morgan Griffith (R., Va.) and Peter Welch (D., Vt.) have reintroduced the Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 1038), which community pharmacies say would squelch a growing burden: retroactive direct and indirect remuneration (DIR) fees. The bill, introduced Wednesday in the House of Representatives, would ban the application

Pharmacy stakeholders unite against DIR fees

Pharmacy stakeholders unite against DIR fees

ALEXANDRIA, Va. — A group of 99 pharmacy retailers, suppliers and organizations applauded House and Senate lawmakers for introducing legislation to clamp down on retroactive direct and indirect remuneration fees imposed by pharmacy benefit managers in Medicare Part D. The National Community Pharmacists Association said the pharmacy stakeholders on Monday wrote letters to the House

Senate bill takes aim at DIR fees

Senate bill takes aim at DIR fees

ALEXANDRIA, Va. — Congressional support continues to build for cracking down on direct and indirect remuneration (DIR) fees. The National Community Pharmacists Association said that four U.S. senators on Monday introduced a bill that would boost transparency in Medicare Part D drug spending and prohibit retroactive DIR fees. The Improving Transparency and Accuracy in Medicare

NCPA backs bill cracking down on DIR fees

NCPA backs bill cracking down on DIR fees

ALEXANDRIA, Va. — The National Community Pharmacists Association has endorsed new legislation designed to raise transparency and accuracy in Medicare Part D prescription drug spending and reporting. NCPA said the bill, the Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 5951), introduced Thursday, also would ban so-called direct and indirect remuneration (DIR)

NCPA razor-focused on DIR fees issue

NCPA razor-focused on DIR fees issue

Persistence is paying off for the National Community Pharmacists Association in its advocacy for more transparency with DIR fees. In a posting in its “The Dose” blog this week, NCPA noted that it continues to build congressional support in getting the Centers for Medicare & Medicaid Services (CMS) to finalize its guidance on direct and

Lawmakers urge CMS to act on DIR fees

Lawmakers urge CMS to act on DIR fees

ALEXANDRIA, Va. — Nearly 50 members of Congress have called on the Centers for Medicare & Medicaid Services (CMS) to finalize its proposed guidance on how Medicare Part D sponsors report pharmacy price concessions, also known as direct and indirect remuneration (DIR) fees. The National Community Pharmacists Association said that 16 senators and 30 representatives

NCPA leads call for more DIR fee transparency

NCPA leads call for more DIR fee transparency

ALEXANDRIA, Va. — The National Community Pharmacists Association has joined with a group of pharmacy industry stakeholders in calling for more clarity about direct and indirect (DIR) fees. NCPA said that this week it teamed up with 21 other organizations — including drug chains, drug suppliers, drug cooperatives and pharmacy associations, among others — in

PP_1170x120_10-25-21